Recurrent hepatitis C after liver transplantation

Mount Sinai Journal of Medicine

Volumn 79, Issue 2, 2012, Pages 190-198

  Sheiner, Patricia ^a   Rochon, Caroline ^b  

^a HARTFORD HOSPITAL   (United States)

^b WESTCHESTER MEDICAL CENTER   (United States)

Author keywords

Donor age; Explant inflammatory grade; Recurrent disease; Steatosis

Indexed keywords

CALCINEURIN INHIBITOR; INTERFERON; RIBAVIRIN;

AGE; CYTOMEGALOVIRUS INFECTION; DIABETES MELLITUS; HEART DEATH; HEPATITIS C; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; LIVER CIRRHOSIS; LIVER GRAFT; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; LIVING DONATION; ORGAN TRANSPLANTATION; POSTOPERATIVE PERIOD; RECURRENT DISEASE; REVIEW; RISK FACTOR; SEX DIFFERENCE; SPLIT LIVER DONATION; STEATOSIS; VIRUS LOAD;

ADULT; ANTIVIRAL AGENTS; CYTOMEGALOVIRUS INFECTIONS; END STAGE LIVER DISEASE; FEMALE; HEPACIVIRUS; HEPATITIS C; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; RECURRENCE; RISK FACTORS; TRANSPLANTATION, HOMOLOGOUS; VIRAL LOAD;

EID: 84859792888     PISSN: 00272507     EISSN: 19317581     Source Type: Journal    
DOI: 10.1002/msj.21300     Document Type: Review

References (72)

1. United Network for Organ Sharing. http://www.unos. org. Accessed September 7, 2011.
2. Wright TL. Liver transplantation in patients with chronic hepatitis B and C. In: Maddrey WC, Sorrell MF, eds. Transplantation of the Liver. 2nd ed. Norwalk, CT: Appleton and Lange; 1995: 477.
3. Ascher NL, Lake JR, Emond J, et al. Liver transplantation for hepatitis C virus-related cirrhosis. Hepatology 1994; 20: 24S-27S. (Pubitemid 24193950)
4. Gane EJ, Portmann BC, Naoumov NV, et al. Long-term outcome of hepatitis C infection after liver transplantation. N Engl J Med 1996; 334: 815-820. (Pubitemid 26099603)
5. Boker KH, Dalley G, Bahr MJ, et al. Long-term outcome of hepatitis C virus infection after liver transplantation. Hepatology 1997; 25: 203-210. (Pubitemid 27015011)
6. Berenguer M. Natural history of recurrent hepatitis C. Liver Transpl 2002; 8 (10 suppl 1):S14-S18. (Pubitemid 35154038)
7. Berenguer M, Prieto M, Rayón JM, et al. Natural history of clinically compensated hepatitis C virus-related graft cirrhosis after liver transplantation. Hepatology 2000; 32 (4 part 1):852-858.
8. Ghobrial RM, Steadman R, Gornbein J, et al. A 10- year experience of liver transplantation for hepatitis C: analysis of factors determining outcome in over 500 patients. Ann Surg 2001; 234: 384-394. (Pubitemid 32847075)
9. Wright TL, Donegan E, Hsu HH, et al. Recurrent and acquired hepatitis C viral infection in liver transplant recipients. Gastroenterology 1992; 103: 317-322.
10. Garcia-Retortillo M, Forns X, Feliu A, et al. Hepatitis C virus kinetics during and immediately after liver transplantation. Hepatology 2002; 35: 680-687. (Pubitemid 34183974)
11. Feray C, Samuel D, Thiers V, et al. Reinfection of liver grafts by hepatitis C virus after liver transplantation. J Clin Invest 1992; 89: 1361-1365.
12. Dickson RC, Pungpapong S, Keaveny AP, et al. Improving graft survival for patients undergoing liver transplantation. Clin Transplant 2011; 25: E345-E355.
13. Lake JR, Shorr JS, Steffen BJ, et al. Differential effects of donor age in liver transplant recipients infected with hepatitis B, hepatitis C and without viral hepatitis. Am J Transplant 2005; 5: 549-557. (Pubitemid 40313347)
14. Alonso O, Loinaz C, Moreno E, et al. Advanced donor age increases the risk of severe recurrent hepatitis C after liver transplantation. Transpl Int 2005; 18: 902-907. (Pubitemid 41726787)
15. Belli LS, Burroughs AK, Burra P, et al. Liver transplantation for HCV cirrhosis: improved survival in recent years and increased severity of recurrent disease in female recipients: results of a long-term retrospective study. Liver Transpl 2007; 13: 733-740. (Pubitemid 46796545)
16. Rayhill SC, Wu YM, Katz DA, et al. Older donor livers show early severe histological activity, fibrosis, and graft failure after liver transplantation for hepatitis C. Transplantation 2007; 84: 331-339. (Pubitemid 47258320)
17. Terrault NA, Shiffman ML, Lok AS, et al. Outcomes in hepatitis C virus-infected recipients of living donor vs. deceased donor liver transplantation. Liver Transpl 2007; 13: 122-129. (Pubitemid 46099981)
18. Jain A, Singhal A, Kashyap R, et al. Comparative analysis of hepatitis C recurrence and fibrosis progression between deceased-donor and living-donor liver transplantation: 8-year longitudinal follow-up. Transplantation 2011; 92: 453-460.
19. Selzner N, Girgrah N, Lilly L, et al. The difference in the fibrosis progression of recurrent hepatitis C after live donor liver transplantation versus deceased donor liver transplantation is attributable to the difference in donor age. Liver Transpl 2008; 14: 1778-1786.
20. Lawal A, Ghobrial R, Te H, et al. Comparison of hepatitis C histological recurrence rates and patient survival between split and deceased donor liver transplantation. Transplant Proc 2007; 39: 3261-3265. (Pubitemid 350251484)
21. Tao R, Ruppert K, Cruz RJ Jr, et al. Hepatitis C recurrence is not adversely affected by the use of donation after cardiac death liver allografts. Liver Transpl 2010; 16: 1288-1295.
22. Taner CB, Bulatoa IG, Keaveny AP, et al. Use of liver grafts from donation after cardiac death donors for recipients with hepatitis C virus. Liver Transpl 2011; 17: 641-649.
23. Baron PW, Sindram P, Higdon D, et al. Prolonged rewarming time during allograft implantation predisposes to recurrent hepatitis C infection after liver transplantation. Liver Transpl 2000; 6: 407-412. (Pubitemid 30489111)
24. Watt KD, Lyden ER, Gulizia JM, et al. Recurrent hepatitis C posttransplant: early preservation injury may predict poor outcome. Liver Transpl 2006; 12: 134-139.
25. Briceño J, Ciria R, Pleguezuelo M, et al. Impact of donor graft steatosis on overall outcome and viral recurrence after liver transplantation for hepatitis C virus cirrhosis. Liver Transpl 2009; 15: 37-48.
26. Bach N, Thung SN, Schaffner F. The histological features of chronic hepatitis C and autoimmune chronic hepatitis: a comparative analysis. Hepatology 1992; 15: 572-577.
27. Scheuer PJ, Ashrafzadeh P, Sherlock S, et al. The pathology of hepatitis C. Hepatology 1992; 15: 567-571.
28. Monto A, Alonzo J, Watson JJ, et al. Steatosis in chronic hepatitis C: relative contributions of obesity, diabetes mellitus, and alcohol. Hepatology 2002; 36: 729-736. (Pubitemid 34977185)
29. Hourigan LF, Macdonald GA, Purdie D, et al. Fibrosis in chronic hepatitis C correlates significantly with body mass index and steatosis. Hepatology 1999; 29: 1215-1219. (Pubitemid 29168757)
30. Adinolfi, L, Gambardella M, Andreana A, et al. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology 2001; 33: 1358-1364. (Pubitemid 32496971)
31. Brandman D, Pingitore A, Lai J, et al. Hepatic steatosis at one year is an additional predictor of subsequent fibrosis severity in liver transplantation recipients with recurrent hepatitis C virus. Liver Transpl 2011; 17: 1380-1386.
32. Machicao VI, Krishna M, Bonatti H, et al. Hepatitis C recurrence is not associated with allograft steatosis within the first year after liver transplantation. Liver Transpl 2004; 10: 599-606. (Pubitemid 38628220)
33. Rubbia-Brandt L, Leandro G, Spahr L, et al. Liver steatosis in chronic hepatitis C: a morphological sign suggesting infection with HCV genotype 3. Histopathology 2001; 39: 119-124. (Pubitemid 34225037)
34. Wang CC, Krantz E, Klarquist J, et al. Acute hepatitis C in a contemporary US cohort: modes of acquisition and factors influencing viral clearance. J Infect Dis 2007; 196: 1474-1482. (Pubitemid 351411983)
35. Jacobson IM, Davis GL, El-Serag H, et al. Prevalence and challenges of liver diseases in patients with chronic hepatitis C virus infection. Clin Gastroenterol Hepatol 2010; 8: 924-933.
36. Lai JC, Verna EC, Brown RS, et al Consortium to Study Health Outcomes in HCV Liver Transplant Recipients (CRUSH-C). Hepatitis C virus-infected women have a higher risk of advanced fibrosis and graft loss after liver transplantation than men. Hepatology 2011; 54: 418-424.
37. Ghabril M, Dickson RC, Krishna M, et al. Explanted liver inflammatory grade predicts fibrosis progression in hepatitis C recurrence. Liver Transpl 2011; 17: 685-694.
38. Khettry U, Huang WY, Simpson MA, et al. Patterns of recurrent hepatitis C after liver transplantation in a recent cohort of patients. Hum Pathol 2007; 38: 443-452. (Pubitemid 46227528)
39. Ciccorossi P, Maina AM, Oliveri F, et al. Viral load 1 week after liver transplantation, donor age and rejections correlate with the outcome of recurrent hepatitis C. Liver Int 2007; 27: 612-619. (Pubitemid 47097310)
40. Burak KW, Kremers WK, Batts KP, et al. Impact of cytomegalovirus infection, year of transplantation, and donor age on outcomes after liver transplantation for hepatitis C. Liver Transpl 2002; 8: 362-369. (Pubitemid 34467371)
41. Singh N, Wannstedt C, Keyes L, et al. Indirect outcomes associated with cytomegalovirus (opportunistic infections, hepatitis C virus sequelae, and mortality) in liver-transplant recipients with the use of preemptive therapy for 13 years. Transplantation 2005; 79: 1428-1434. (Pubitemid 40734808)
42. Teixeira R, Pastacaldi S, Davies S, et al. The influence of cytomegalovirus viraemia on the outcome of recurrent hepatitis C after liver transplantation. Transplantation 2000; 70: 1454-1458.
43. Humar A, Kumar D, Raboud J, et al. Interactions between cytomegalovirus, human herpesvirus-6, and the recurrence of hepatitis C after liver transplantation. Am J Transplant 2002; 2: 461-466. (Pubitemid 36306888)
44. AlDosary AA, Ramji AS, Elliott TG, et al. Post-liver transplantation diabetes mellitus: an association with hepatitis C. Liver Transpl 2002; 8: 356-361. (Pubitemid 34467370)
45. Khalili M, Lim JW, Bass N, et al. New-onset diabetes mellitus after liver transplantation: the critical role of hepatitis C infection. Liver Transpl 2004; 10: 349-355. (Pubitemid 38380307)
46. Foxton MR, Quaglia A, Muiesan P, et al. The impact of diabetes mellitus on fibrosis progression in patients transplanted for hepatitis C. Am J Transplant 2006; 6: 1922-1929. (Pubitemid 44024965)
47. Hanouneh IA, Feldstein AE, McCullough AJ, et al. The significance of metabolic syndrome in the setting of recurrent hepatitis C after liver transplantation. Liver Transpl 2008; 14: 1287-1293.
48. Berenguer M, Prieto M, Córdoba J, et al. Early development of chronic active hepatitis in recurrent hepatitis C virus infection after liver transplantation: association with treatment of rejection. J Hepatol 1998; 28: 756-763. (Pubitemid 28223478)
49. Prieto M, Berenguer M, Rayón JM, et al. High incidence of allograft cirrhosis in hepatitis C virus genotype 1b infection following transplantation: relationship with rejection episodes. Hepatology 1999; 29: 250-256. (Pubitemid 29024010)
50. Sheiner, P Schwartz ME, Mor E, et al. Severe or multiple rejection episodes are associated with early recurrence of hepatitis C after orthotopic liver transplantation. Hepatology 1995; 21: 30-34.
51. Rosen HR, Shackleton CR, Higa L, et al. Use of OKT3 is associated with early and severe recurrence ofhepatitis C after liver transplantation. Am J Gastroenterol 1997; 92: 1453-1457. (Pubitemid 27412863)
52. Kim RD, Mizuno S, Sorensen JB, et al. Impact of calcineurin inhibitors on hepatitis C recurrence after liver transplantation. Dig Dis Sci 2011; doi:10.1007/s10620- 011-1871-z.
53. Irish WD, Arcona S, Bowers D, et al. Cyclosporine versus tacrolimus treated liver transplant recipients with chronic hepatitis C: outcomes analysis of the UNOS/ OPTN database. Am J Transplant 2011; 11: 1676-1685.
54. Vargas V, Charco R, Castells L, et al. Alpha-interferon for acute hepatitis C in liver patients. Transplant Proc 1995; 27: 1222-1223.
55. Charlton M. Hepatitis C infection in liver transplantation. Am J Transplant 2001; 1: 197-203. (Pubitemid 33674162)
56. Gopal DV, Rabkin JM, Berk BS, et al. Treatment of progressive hepatitis C recurrence after liver transplantation with combination interferon plus ribavirin. Liver Transpl 2001; 7: 181-190. (Pubitemid 32243812)
57. Narayanan Menon KV, Poterucha JJ, El-Amin OM, et al. Treatment of post-transplantation recurrence of hepatitis C with interferon and ribavirin: lessons on tolerability and efficacy. Liver Transpl 2002; 8: 623-629. (Pubitemid 34752711)
58. Bizollon T, Palazzo U, Ducerf C, et al. Pilot study of the combination of interferon alfa and ribavirin as therapy of recurrent hepatitis C after liver transplantation. Hepatology 1997; 26: 500-504. (Pubitemid 27328333)
59. De Vera ME, Smallwood GA, Rosado K, et al. Interferon and ribavirin for the treatment of recurrent hepatitis C after liver transplantation. Transplantation 2001; 71: 678-686. (Pubitemid 32268074)
60. Ross AS, Bhan AK, Pascual M, et al. Pegylated interferon alpha-2b plus ribavirin in the treatment of post-liver transplant recurrent hepatitis C. Clin Transplant 2004; 18: 166-173. (Pubitemid 38404647)
61. Wright TL, Combs C, Kim M. Interferon-alpha therapy for hepatitis C after liver transplantation. Hepatology 1994; 20(4 part 1): 773-779. (Pubitemid 24296480)
62. Mazzaferro V, Regalia E, Pulvirenti A. Prophylaxis against HCV recurrence after liver transplantation: effect of interferon and ribavirin combination. Transplant Proc 1997; 29: 519-521. (Pubitemid 27123515)
63. Hakil AO, McGuire B, Crippin J, et al. A pilot study of interferon alfa and ribavirin combination in liver transplant recipients with recurrent hepatitis C. Hepatology 2002; 36: 1253-1258. (Pubitemid 35253443)
64. Firpi RJ, Abdelmalek MF, Soldevila-Pico C, et al. Combination of interferon alfa-2b and ribavirin in liver transplant recipients with histological recurrent hepatitis C. Liver Transpl 2002; 8: 1000-1006. (Pubitemid 35363625)
65. Gordon FD, Brown RS, Kwo P, et al. Peginterferon alfa-2b and ribavirin for hepatitis C recurrence post orthotopic liver transplantation (OLT): final results from the PROTECT Study. Paper presented at: 45th Annual Meeting of the European Association for the Study of the Liver (EASL 2010); April 14-18, 2010; Vienna, Austria.
66. Didier S, Bizollon T, Feray C, et al. Interferon-a 2b plus ribavirin in patients with chronic hepatitis C after liver transplantation: a randomized study. Gastroenterology 2003; 124: 642-650. (Pubitemid 36268483)
67. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-982.
68. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 2001; 358: 958-965. (Pubitemid 32913521)
69. Forestier N, Reesink HW, Weegink CJ, et al. Antiviral activity of telaprevir (VX-950) and peginterferon alfa-2a in patients with hepatitis C. Hepatology 2007; 46: 640-648. (Pubitemid 47436108)
70. Kieffer TL, Sarrazin C, Miller JS, et al. Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients. Hepatology 2007; 46: 631-639. (Pubitemid 47436107)
71. Garg V, van Heeswijk R, Lee JE, et al. Effect of telaprevir on the pharmacokinetics of cyclosporine and tacrolimus. Hepatology 2011; 54: 20-27.
72. Charlton M. Telaprevir boceprevir, cytochrome P450 and immunosuppressive agents-a potentially lethal cocktail. Hepatology 2011; 54: 3-5.